-
New national statistics show that about one in nine (11% or 5.8 million) women ages 15 to 44 had ever used emergency contraception (EC) in 2006-2010, up from 4.2% in 2002.1 Young adult women ages 20-24 were the most likely to have ever used EC about one in four (23%) indicated they had utilized the method.
-
While use of intrauterine devices (IUDs) represents a highly effective form of birth control, many women still are not getting proper information about it, results of a new survey indicate.1 Only one-fifth of the women surveyed knew that intrauterine devices were more effective in preventing pregnancy than oral contraception, while only 29% knew that IUDs are cheaper over time than pills.
-
Trichomoniasis, or trich, is the most common curable sexually transmitted infection (STI) in the United States, yet only one in five women are familiar with it, according to a new survey commissioned by the American Sexual Health Association (ASHA) in Research Triangle Park, NC.
-
-
A new American College of Obstetricians and Gynecologists committee opinion has endorsed use of the U.S. Selected Practice Recommendations for Contraceptive Use, 2013 (US SPR) in counseling patients about how to most effectively use current birth control methods.
-
One problem that policymakers are confronting as they implement the Affordable Care Act (ACA) is that even if people gain health insurance coverage, they might not always be willing to use it.
-
In a national study, menstrual disorders accounted for 19.1% of 20.1 million physician office visits for gynecologic conditions over two years.
-
More women are now choosing long-acting reversible contraceptive (LARC) methods, such as intrauterine devices (IUDs) and the subdermal contraceptive implant. The number of women using LARC methods rose from 2.4% in 2002 to 8.5% in 2009.
-
Make the first reproductive health visit for a young teen a successful one by using the HEEADSSS (Home environment, Education and employment, Eating, peer-related Activities, Drugs, Sexuality, Suicide/depression, and Safety from injury and violence) method of interviewing in performing a psychosocial review of systems.
-
Just-released results from international trials indicate a potential vaccine, designed to protect against nine HPV strains, might be the next step in cervical cancer protection. In the pivotal Phase III efficacy study, the investigational 9-valent HPV vaccine prevented approximately 97% of cervical, vaginal, and vulvar pre-cancers caused by HPV types 31, 33, 45, 52, and 58.
